These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30301530)

  • 1. Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1.
    Fan P; Ma J; Jin X
    Biochem Biophys Res Commun; 2018 Nov; 505(3):830-836. PubMed ID: 30301530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.
    Hu G; He N; Cai C; Cai F; Fan P; Zheng Z; Jin X
    Pancreatology; 2019 Mar; 19(2):383-389. PubMed ID: 30670333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FUBP1 promotes the proliferation of lung squamous carcinoma cells and regulates tumor immunity through PD-L1.
    Yu J; Peng W; Xue Y; Li Y; Yang L; Geng Y
    Allergol Immunopathol (Madr); 2022; 50(5):68-74. PubMed ID: 36086966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
    Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
    BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.
    Yan R; Li J; Zhou Y; Yao L; Sun R; Xu Y; Ge Y; An G
    Life Sci; 2020 Jan; 241():117150. PubMed ID: 31837335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
    Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
    Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
    Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
    Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
    Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM
    World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.
    Ebine K; Kumar K; Pham TN; Shields MA; Collier KA; Shang M; DeCant BT; Urrutia R; Hwang RF; Grimaldo S; Principe DR; Grippo PJ; Bentrem DJ; Munshi HG
    Sci Rep; 2018 Sep; 8(1):13225. PubMed ID: 30185888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
    Zhang X; Huang X; Xu J; Li E; Lao M; Tang T; Zhang G; Guo C; Zhang X; Chen W; Yadav DK; Bai X; Liang T
    Nat Commun; 2021 Jul; 12(1):4536. PubMed ID: 34315872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
    Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer.
    Zhou Y; Jin X; Yu H; Qin G; Pan P; Zhao J; Chen T; Liang X; Sun Y; Wang B; Ren D; Zhu S; Wu H
    Theranostics; 2022; 12(5):2080-2094. PubMed ID: 35265200
    [No Abstract]   [Full Text] [Related]  

  • 15. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis.
    Tsukamoto M; Imai K; Ishimoto T; Komohara Y; Yamashita YI; Nakagawa S; Umezaki N; Yamao T; Kitano Y; Miyata T; Arima K; Okabe H; Baba Y; Chikamoto A; Ishiko T; Hirota M; Baba H
    Cancer Sci; 2019 Jan; 110(1):310-320. PubMed ID: 30426611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy.
    Sun K; Zhang X; Lao M; He L; Wang S; Yang H; Xu J; Tang J; Hong Z; Song J; Guo C; Li M; Liu X; Chen Y; Zhang H; Zhou J; Lin J; Zhang S; Hong Y; Huang J; Liang T; Bai X
    Mol Ther; 2023 Oct; 31(10):2929-2947. PubMed ID: 37515321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
    Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
    J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
    Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
    Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
    Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS
    Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.